These findings suggest that FADD might be a potential intervention target benefiting for the treatment of obesity, hepatic steatosis, and other metabolic disorders, and further research in this area will help to understand the pathology of human obesity‐related diseases. This evidence concerns the gene FADD and Other metabolic disease.